Skip to content
Use caution Drug recall · FDA · Published November 25, 2014

Hospira Recalls Dacarbazine Vials Due to Discoloration

Hospira Inc. recalls specific lots of Dacarbazine Injection, USP 200mg vials due to potential pink discoloration. Check lot numbers and expiration dates.

🇺🇸 FDA recall #D-0313-2015DrugHospira ›
Take action

Contact the company

Recalling firmHospira Inc.275 N Field Dr · Lake Forest, IL 60045-2579
✎ GovInfoNow plain-language explainer

What happened, in plain English

Hospira Inc. is recalling 3,306 vials of Dacarbazine, Injection, USP 200mg because the reconstituted solution may appear pink instead of its normal colorless to pale yellow appearance when stored as labeled. This specific batch was manufactured in Australia and distributed nationwide. The recall affects a Class III product, which typically indicates a hazard that is unlikely to cause serious adverse health consequences but could still pose risks depending on usage. Read more at govinfonow.com/recall/45144-hospira-inc-recalls-dacarbazine-injection-usp-200mg-vials-packaged-in.

Source Summary by GovInfoNow · govinfonow.com/recall/45144-hospira-inc-recalls-dacarbazine-injection-usp-200mg-vials-packaged-in · Updated October 12, 2026 · FDA enforcement record: FDA #D-0313-2015

Cite this page

“Hospira Recalls Dacarbazine Vials Due to Discoloration.” GovInfoNow, updated October 12, 2026. https://govinfonow.com/recall/45144-hospira-inc-recalls-dacarbazine-injection-usp-200mg-vials-packaged-in. Based on FDA recall #D-0313-2015 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0313-2015%22&limit=1).

Why it’s dangerous

The primary hazard is a visual change in the drug's appearance; the reconstituted solution may turn pink instead of remaining colorless to pale yellow. While the record does not explicitly state that the discoloration renders the drug ineffective or toxic, such changes in pharmaceutical products can indicate stability issues or contamination, necessitating caution before administration.

Who’s affected

Patients receiving chemotherapy who have been prescribed Dacarbazine Injection, USP 200mg from the specific recalled lots. Healthcare providers administering this medication are also directly affected.

How to tell if you have this one

Look for Dacarbazine, Injection, USP 200mg vials manufactured by Hospira Australia. Specifically check for NDC 61703-327-22 and Lot # B032223AA with an expiration date of July 2016.

  • Brand
    Hospira
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Inventory

    Verify if you have vials matching NDC 61703-327-22, Lot # B032223AA, expiring in July 2016.

  2. Contact Provider

    If you have the recalled product, contact your healthcare provider or pharmacist for instructions on return or disposal.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 2.1 years after the firm started it.

1. Firm started the recall: Nov 25, 201412. FDA classified it Class III: Dec 22, 201423. Published in FDA’s Enforcement Report: Dec 31, 201434. FDA terminated the recall: Dec 15, 2016420142016
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0313-2015 (November 25, 2014) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0313-2015 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 12, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA